Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905626 | 0.91 | PDE10A (0.46) | PDE10APDE2APDE5ATP53MAPT | |
| SCHEMBL2387077 | 0.87 | PDE10A (0.41) | PDE10APDE2APDE5A | |
| SCHEMBL2387471 | 0.85 | PDE10A (0.43) | PDE10APDE2APDE5A | |
| SCHEMBL2384764 | 0.85 | PDE10A (0.41) | PDE10APDE2APDE5A | |
| SCHEMBL2387885 | 0.83 | HIF1A (0.48) | PDE10APDE2APDE5AMAPT | |
| SCHEMBL21003964 | 0.83 | PDE10A (0.45) | PDE10APDE2APDE5AMAPTABCB1 | |
| SCHEMBL2386468 | 0.81 | PDE10A (0.48) | PDE10APDE2APDE5AMAPT | |
| SCHEMBL2387130 | 0.81 | PDE10A (0.45) | PDE10APDE2APDE5AMAPTABCB1 | |
| SCHEMBL2387860 | 0.80 | MKNK1 (0.44) | PDE10APDE2APDE5AMAPTABCB1 | |
| SCHEMBL2387579 | 0.80 | PDE10A (0.49) | PDE10APDE2APDE5ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 9/4885PDE5A 11/4885 |
| US-20140228581-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 9/4885PDE5A 11/4885 |
| US-20130196994-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 9/4885PDE5A 11/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 9/4885PDE5A 11/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | PDE10A 1/4885PDE2A 9/4885PDE5A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.